- Platinum sensitivity and non-cross-resistance of cisplatin analogue with cisplatin in recurrent cervical cancer
-
Takekuma M, Kuji S, Tanaka A, Takahashi , Abe M, Hirashima
- KMID: 2160804
- J Gynecol Oncol.
- 2015 Jul;26(3):185-192.
- doi: 10.3802/jgo.2015.26.3.185
OBJECTIVE: The concept of platinum sensitivity and cross-resistance among platinum agents are widely known in the management of recurrent ovarian cancer. The aim of this study was to evaluate two... -
- CITED
-
- Close
- SHARE
-
- Close
- The relationship between positive peritoneal cytology and the prognosis of patients with FIGO stage I/II uterine cervical cancer
-
Kuji S, Hirashima , Komeda S, Tanaka A, Abe M, Takahashi , Takekuma M
- KMID: 1708330
- J Gynecol Oncol.
- 2014 Apr;25(2):90-96.
- doi: 10.3802/jgo.2014.25.2.90
OBJECTIVE: The purpose of this study was to assess whether peritoneal cytology has prognostic significance in uterine cervical cancer. METHODS: Peritoneal cytology was obtained in 228 patients with carcinoma of the... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical utility of CA-125 in the management of uterine carcinosarcoma
-
Matsuo K, Ross MS, Yunokawa M, Johnson MS, Machida H, Omatsu K, Klobocista MM, Im DD, Satoh S, Baba T, Ikeda Y, Bush SH, Hasegawa K, Blake EA, Takekuma M, Shida M, Nishimura , Adachi S, Pejovic T, Takeuchi S, Yokoyama T, Ueda Y, Iwasaki K, Miyake TM, Yanai S, Nagano T, Takano T, Shahzad MM, Ueland FR, Kelley JL, Roman LD
- KMID: 2431233
- J Gynecol Oncol.
- 2018 Nov;29(6):e88.
- doi: 10.3802/jgo.2018.29.e88
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Phase 2 single-arm study on the efficacy and safety of niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer
-
Okamoto A, Kondo E, Nakamura T, Yanagida S, Hamanishi J, Harano K, Hasegawa K, Hirasawa T, Hori K, Komiyama S, Matsuura M, Nakai H, Nakamura H, Sakata J, Tabata T, Takehara K, Takekuma M, Yokoyama Y, Kase Y, Sumino S, Soeda J, Suri A, Aoki D, Sugiyama T
- KMID: 2526354
- J Gynecol Oncol.
- 2021 Mar;32(2):e16.
- doi: 10.3802/jgo.2021.32.e16
Objective: To evaluate the efficacy and safety of niraparib in Japanese women with heavily pretreated ovarian cancer. Methods: This Phase 2 open-label, single-arm study enrolled Japanese women with homologous recombination deficiency-positive... -
- CITED
-
- Close
- SHARE
-
- Close
